Unmet Patient Needs in Rheumatic Disease

Nov 23, 2021, 06:12 PM

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases as well as Janssen’s work in scientific innovation that allows patients to live their lives more unburdened by their disease. Chakravarty is the Sr Director and Strategic Lead in the Rheumatology Therapeutics area at Janssen. Time stamps: 0:45: Why do you believe fewer than 10% of patients achieve sustained clinical remission? 3:36: What are some of the unmet needs in immune-mediated diseases? 5:41: Are there any conditions that are especially suffering from this? 9:44: What are some of the scientific and experience innovations that Janssen utilizes to help drive treatment advancement? 12:21: How does Janssen focus on where the impact of disease on patients where it is highest and gaps in treatment are greatest? 16:38: How do you believe we can achieve greater numbers of patients in remission? 20:29: Can you tell me a bit about how collaboration helps patients navigate their own treatment j

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases as well as Janssen’s work in scientific innovation that allows patients to live their lives more unburdened by their disease. Chakravarty is the Sr Director and Strategic Lead in the Rheumatology Therapeutics area at Janssen.

Time stamps: 

0:45: Why do you believe fewer than 10% of patients achieve sustained clinical remission?

3:36: What are some of the unmet needs in immune-mediated diseases? 

5:41: Are there any conditions that are especially suffering from this? 

9:44: What are some of the scientific and experience innovations that Janssen utilizes to help drive treatment advancement? 

12:21: How does Janssen focus on where the impact of disease on patients where it is highest and gaps in treatment are greatest?

16:38: How do you believe we can achieve greater numbers of patients in remission?
20:29: Can you tell me a bit about how collaboration helps patients navigate their own treatment journey? 

22:38: Is there anything else you’d like our audience to know?